← RetinalGenix Technologies Inc. (RTGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RetinalGenix Technologies Inc. (RTGN)
Surgical & Medical Instruments & Apparatus · market cap $75M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| N-acetylcysteine | Phase 3 | Retinitis Pigmentosa |
| ketoconazole | Phase 2 | Chronic Central Serous Chorioretinopathy |
| Anecortave Acetate Sterile suspension 15 mg | Phase 2 | Chronic Central Serous Chorioretinopathy |
| Metformin | Phase 2 | Age-Related Macular Degeneration |
Price & technical context
3-month
-0.2%
6-month
+24.7%
12-month
+12.7%
52-wk range
$3.20–$4.00
vs 50-day MA
-0.2%
vs 200-day MA
+10.5%
Realized vol
27.5%
Max drawdown
-68.4%
Daily closes through 2026-09-29. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RTGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.